Abstract
β-thalassemia major is one of the most common hematologic disorders in the world. It causes severe anemia and patients require regular blood transfusions, which causes different complications such as iron overload and alloimmunization. Regulatory T cells (Tregs) have an important role in regulation of immune responses. FoxP3 is the major marker of Tregs and its expression can be influenced by different factors. GDF-15 is another gene that plays a role in iron homeostasis and regulation of immune system in different diseases. The aim of this study was to assess the frequency of Tregs and FoxP3/GDF-15 gene expression in β-thalassemia major patients with and without alloantibody as well as its correlation with different factors such as serum ferritin and folate levels. This study was conducted on 68 β-thalassemia major patients with and without alloantibodies in comparison with 20 healthy individuals with matched age and sex as control group. Enzyme-linked immunosorbent assay (ELISA), flow cytometry, and real-time PCR were performed in order to evaluate serum ferritin and folate levels, frequency of Tregs, and the expression of FoxP3 and GDF-15 genes, respectively. The percentage and absolute count of Tregs were increased in patients compared with controls (P = 0.0003), but there was no difference between responders and non-responders (P > 0.05). The Tregs count correlated positively with serum ferritin. No correlation was observed between target genes and serum ferritin and folate, but there was a positive significant correlation between the expression of FoxP3 and GDF-15 genes, which shows the immunosuppressive role of GDF-15.
References
Mohamed SY (2017) Thalassemia major: transfusion and chelation or transplantation. Hematol Oncol Stem Cell Ther. https://doi.org/10.1016/j.hemonc.2017.05.022
Weatherall D, Williams T, Allen S, O’Donnell A (2010) The population genetics and dynamics of the thalassemias. Hematol Oncol Clin North Am 24(6):1021–1031
Modell B, Darlison M (2008) Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ 86(6):480–487
Wu HP, Lin CL, Chang YC, Wu KH, Lei RL, Peng CT, Weng T, Tai YM, Chao YH (2017) Survival and complication rates in patients with thalassemia major in Taiwan. Pediatr Blood Cancer 64(1):135–138. https://doi.org/10.1002/pbc.26181
Memon AS, Memon R, Muhammad AT, Ali SA, Siddiqui AJ (2017) Splenectomy: does it help in patients with thalassemia major. J Liaquat Uni Med Health Sci 16(1):20–23
Caocci G, Orofino MG, Vacca A, Piroddi A, Piras E, Addari MC, Caria R, Pilia MP, Origa R, Moi P, La Nasa G (2017) Long-term survival of beta thalassemia major patients treated with hematopoietic stem cell transplantation compared with survival with conventional treatment. Am J Hematol 92(12):1303–1310. https://doi.org/10.1002/ajh.24898
Galanello R, Sanna S, Perseu L, Sollaino MC, Satta S, Lai ME, Barella S, Uda M, Usala G, Abecasis GR (2009) Amelioration of Sardinian β 0 thalassemia by genetic modifiers. Blood 114(18):3935–3937
Rivella S (2015) β-thalassemias: paradigmatic diseases for scientific discoveries and development of innovative therapies. Haematologica 100(4):418–430
Mishra AK, Tiwari A (2013) Iron overload in beta thalassaemia major and intermedia patients. Maedica 8(4):328–332
Cassat JE, Skaar EP (2013) Iron in infection and immunity. Cell Host Microbe 13(5):509–519
Zanella S, Garani MC, Borgna-Pignatti C (2016) Malignancies and thalassemia: a review of the literature. Ann N Y Acad Sci 1368(1):140–148
Karimi M, Nikrooz P, Kashef S, Jamalian N, Davatolhagh Z (2007) RBC alloimmunization in blood transfusion-dependent β-thalassemia patients in southern Iran. Int J Lab Hematol 29(5):321–326
Yazdanbakhsh K, Ware RE, Noizat-Pirenne F (2012) Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood 120(3):528–537
Javad G, Saeid A, Mohammadmehdi N (2011) Thalassemia and immune system dysfunction-review article. Int J Curr Res 3:105–108
Bacchetta R, Gambineri E, Roncarolo M-G (2007) Role of regulatory T cells and FOXP3 in human diseases. J Allergy Clin Immunol 120(2):227–235
Sakaguchi S, Miyara M, Costantino CM, Hafler DA (2010) FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 10(7):490–500
Bao W, Yu J, Heck S, Yazdanbakhsh K (2009) Regulatory T-cell status in red cell alloimmunized responder and nonresponder mice. Blood 113(22):5624–5627
Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, He XY, Zhang HP, Donnellan M, Mahler S, Pryor K (1997) MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-β superfamily. Proc Natl Acad Sci 94(21):11514–11519
Tanno T, Bhanu NV, Oneal PA, Goh S-H, Staker P, Lee YT, Moroney JW, Reed CH, Luban NL, Wang R-H (2007) High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 13(9):1096–1101
Corre J, Hébraud B, Bourin P (2013) Concise review: growth differentiation factor 15 in pathology: a clinical role? Stem Cells Transl Med 2(12):946–952
Prati D (2000) Benefits and complications of regular blood transfusion in patients with beta-thalassaemia major. Vox Sang 79(3):129–137
Singer ST, Wu V, Mignacca R, Kuypers FA, Morel P, Vichinsky EP (2000) Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly Asian descent. Blood 96(10):3369–3373
Lal G, Bromberg JS (2009) Epigenetic mechanisms of regulation of Foxp3 expression. Blood 114(18):3727–3735
Moshtaghi-Kashanian G-R, Gholamhoseinian A, Hoseinimoghadam A, Rajabalian S (2006) Splenectomy changes the pattern of cytokine production in β-thalassemic patients. Cytokine 35(5–6):253–257
Bozdogan G, Erdem E, Demirel GY, Yildirmak Y (2010) The role of Treg cells and FoxP3 expression in immunity of β-thalassemia major and β-thalassemia trait patients. Pediatr Hematol Oncol 27(7):534–545
Mahmoud S, Mohamed G, Hakeem G, Higazi A, Nafady A, Farag N, Mahrous D, Kamal N, Hassan Z, Aziz E (2017) Comparison of the immunity status in-between children with [beta]-thalassaemia major receiving different treatment modalities: a single Egyptian district study. Immunome Res 13(1):1–8
Gharagozloo M, Karimi M, Amirghofran Z (2009) Double-faced cell-mediated immunity in β-thalassemia major: stimulated phenotype versus suppressed activity. Ann Hematol 88(1):21–27
Wendell F, Kinney TR, Levy PS (1990) Transfusion and alloimmunization in sickle cell disease. Blood 76(7):1431–1437
Gombar S, Parihar K, Choudhary M (2018) Comparative study of serum ferritin and vitamin D in thalassemia patients with healthy controls. Int J Res Med Sci 6(2):693–695
Gray CP, Arosio P, Hersey P (2002) Heavy chain ferritin activates regulatory T cells by induction of changes in dendritic cells. Blood 99(9):3326–3334
Biamonte F, Zolea F, Bisognin A, Di Sanzo M, Saccoman C, Scumaci D, Aversa I, Panebianco M, Faniello MC, Bortoluzzi S (2015) H-ferritin-regulated microRNAs modulate gene expression in K562 cells. PLoS One 10(3):e0122105
Indrasari ND, Timan IS, Amalia P (2017) Expression of hepcidin and growth differentiation factor 15 (GDF-15) levels in thalassemia patients with iron overload and positive anti hepatitis C virus. The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy 17(2):106–111
Arkoumani M, Papadopoulou-Marketou N, Nicolaides NC, Kanaka-Gantenbein C, Tentolouris N, Papassotiriou I (2019) The clinical impact of growth differentiation factor-15 in heart disease: a 2019 update. Crit Rev Clin Lab Sci:1–12. https://doi.org/10.1080/10408363.2019.1678565
Carlsson AC, Nowak C, Lind L, Östgren CJ, Nyström FH, Sundström J, Carrero JJ, Riserus U, Ingelsson E, Fall T (2019) Growth differentiation factor 15 (GDF-15) is a potential biomarker of both diabetic kidney disease and future cardiovascular events in cohorts of individuals with type 2 diabetes: a proteomics approach. Ups J Med Sci:1–7. https://doi.org/10.1080/03009734.2019.1696430
Sharma A, Stevens SR, Lucas J, Fiuzat M, Adams KF, Whellan DJ, Donahue MP, Kitzman DW, Piña IL, Zannad F (2017) Utility of growth differentiation factor-15, a marker of oxidative stress and inflammation, in chronic heart failure: insights from the HF-ACTION study. JACC: Heart Fail 5(10):724–734
Porter JB, Cappellini MD, Kattamis A, Viprakasit V, Musallam KM, Zhu Z, Taher AT (2017) Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions. Br J Haematol 176(2):288–299
Roth P, Junker M, Tritschler I, Mittelbronn M, Dombrowski Y, Breit SN, Tabatabai G, Wick W, Weller M, Wischhusen J (2010) GDF-15 contributes to proliferation and immune escape of malignant gliomas. Clin Cancer Res 16(15):3851–3859
Zhou Z, Li W, Song Y, Wang L, Zhang K, Yang J, Zhang W, Su H, Zhang Y (2013) Growth differentiation factor-15 suppresses maturation and function of dendritic cells and inhibits tumor-specific immune response. PLoS One 8(11):e78618
Zhang Y, Zhang G, Zhao D, MacAlister V, Mele T, Liu K, Zheng X (2018) GDF15 regulates Malat-1 circular RNA and inactivates NFКB signaling leading to immune tolerogenic DCs for preventing alloimmune rejection in heart transplantation. Front Immunol 9:2407
Mojtahedzadeh F, Kosaryan M, Mahdavi M-R, Akbari J (2006) The effect of folic acid supplementation in beta-thalassemia major: a randomized placebo-controlled clinical trial. Arch Iran Med 9(3):266–268
Mansouri R, Moogooei M, Moogooei M, Razavi N, Mansourabadi AH (2016) The role of vitamin D3 and vitamin B9 (folic acid) in immune system. Int J Epidemiol Res 3(1):69–85
Kinoshita M, Kayama H, Kusu T, Yamaguchi T, Kunisawa J, Kiyono H, Sakaguchi S, Takeda K (2012) Dietary folic acid promotes survival of Foxp3+ regulatory T cells in the colon. J Immunol 189(6):2869–2878
Acknowledgments
The authors would like to thank the staffs of Diagnostic Laboratory Sciences and Technology Research Center. Also, the authors wish to thank Mr. H. Argasi at the Research Consultation Center (RCC) of Shiraz University of Medical Sciences for his invaluable assistance in editing this manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
The study was approved by the local ethics committee of Shiraz University of Medical Sciences. Written informed consent was obtained from each patient enrolled in the study.
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Shokrgozar, N., Amirian, N., Ranjbaran, R. et al. Evaluation of regulatory T cells frequency and FoxP3/GDF-15 gene expression in β-thalassemia major patients with and without alloantibody; correlation with serum ferritin and folate levels. Ann Hematol 99, 421–429 (2020). https://doi.org/10.1007/s00277-020-03931-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-020-03931-9